Challenger thrombolytic prevails in battle of the clot-busters

Australian trial could pave the way for a change in bridging therapy

A cheaper thrombolytic appears to double the chances of reperfusion in patients with ischaemic stroke prior to thrombectomy, compared with the standard drug, Australian research shows.

brain CT scan

The double-blinded, randomised controlled trial of 200 patients found tenecteplase was non-inferior to alteplase, and patients had better functional outcomes after its use.

Reperfusion of more than 50% of the ischaemic area or dissolution of the clot occurred in 22% of patients treated with tenecteplase compared with 10% of those given alteplase, according to the researchers led by neurologist